IceCure Medical (ICCM) to Release Quarterly Earnings on Wednesday

Key Points

• IceCure Medical (ICCM) is set to announce its Q2 2025 earnings on August 13th, with analysts predicting a loss of ($0.06) per share and revenue of $0.90 million.
• The company previously reported a loss of ($0.06) EPS in its last quarterly results, exceeding analysts' expectations of ($0.08) EPS.
• Analysts have mixed ratings on the stock, with Wall Street Zen downgrading it from "hold" to "sell," while HC Wainwright maintains a "buy" rating with a target price of $2.50.

IceCure Medical (NASDAQ:ICCM - Get Free Report) is expected to be issuing its Q2 2025 quarterly earnings data before the market opens on Wednesday, August 13th. Analysts expect the company to announce earnings of ($0.06) per share and revenue of $0.90 million for the quarter.

IceCure Medical (NASDAQ:ICCM - Get Free Report) last released its earnings results on Wednesday, May 28th. The company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.02. IceCure Medical had a negative return on equity of 182.26% and a negative net margin of 467.37%. The firm had revenue of $0.73 million for the quarter, compared to the consensus estimate of $0.75 million. During the same quarter in the previous year, the company posted ($0.08) EPS. On average, analysts expect IceCure Medical to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

IceCure Medical Stock Down 3.9%

Shares of ICCM traded down $0.03 during midday trading on Monday, reaching $0.79. 1,399,602 shares of the stock were exchanged, compared to its average volume of 633,324. The company has a current ratio of 1.89, a quick ratio of 1.48 and a debt-to-equity ratio of 0.02. The company has a market capitalization of $46.55 million, a P/E ratio of -2.83 and a beta of 0.32. IceCure Medical has a 52 week low of $0.48 and a 52 week high of $1.66. The company's 50 day moving average is $1.00 and its two-hundred day moving average is $1.14.

Analysts Set New Price Targets

A number of brokerages have recently commented on ICCM. Wall Street Zen cut shares of IceCure Medical from a "hold" rating to a "sell" rating in a research note on Saturday, July 12th. HC Wainwright restated a "buy" rating and set a $2.50 target price on shares of IceCure Medical in a report on Thursday, May 29th.

About IceCure Medical

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.